

Patient ID*: 12BKC1292

AGE: 57/ Male

COUNTRY: India

DIAGNOSIS: Optic Nerve Atrophy

On the morning of 10th July 2009 when the patient woke up he noticed a small white spot at the center of his vision and by the evening, he could not see anything and was totally blind. With all kinds of treatment there was little improvement and the patient was diagnosed with optic nerve atrophy untreatable by any conventional method.

REASON FOR COMING FOR TREATMENT: The patient had tried all available conventional treatments in the best eye hospitals in India and abroad. He found no improvement in his condition, since there is no allopathic treatment available to patients. He then thought of trying new emerging unproven treatments like stem cell therapy as he had heard of its benefits in optic atrophy.

TREATMENT: Mesenchymal stem cells derived from Wharton's jelly, of which he received 7 injections of stem cells, 3 through the intravenous route in a dose of 1 million cells/ kg body weight, 2 injections of adequate cells through the intrathecal route and 2 through the retro-bulbar route.

START DATE OF TREATMENT: 2nd July 2012

BEFORE TREATMENT: He appreciated only hand movements close to face in one eye (R) and perception of light (L) only in the upper and lateral quadrants (both eyes) in the beginning.

AFTER TREATMENT: Later during discharge, he was able to appreciate hand movements in all 4 quadrants and that too at a distance of 2 m (R) and 1.5 m (L) in the respective eyes. He also reported having seen flashes of a bus on the street, his wife and himself in the mirror clearly for a couple of seconds during his stay in the hospital, something that happened for the first time in the past 3 years. His pupillary diameter of both eyes improved from 5mm at admission to 3.5 mm at discharge, suggesting that his optic pathway was handling more light signals after stem cell infusions.

Disclaimer: Stem cell therapy using tissue stem cells does not fall under the realm of accepted modalities of treatment. The results reaped from this therapy may differ from person to person.

**To protect identity names of patients not disclosed.*